Clinical Trial Update: Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of ALS-L1023 in combination with ranibizumab for wet age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• ALS-L1023
• Ranibizumab (ranibizumab)

Snippet

Sponsor: AngioLab, Inc. | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED